Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vaccination halts tumour growth in rhinos
white rhino
“If the oestrous cycle of female rhinoceros can be interrupted by a simple inoculation and, later on, fertility can recover again, the vaccination is a huge veterinary advance."
Improvac reduced size of innocuous tumour, scientists report

For the first time a vaccination has successfully stopped the growth and regeneration of innocuous tumours in rhinos, researchers say.

Southern white rhinos and greater one-horned rhinos were injected with the ‘Improvac’ serum, which affects the release of hormones and causes the female oestrus cycle to cease, thereby reducing hormone-dependent tumours.

Three months after the vaccination, scientists say ultrasound examination showed a reduction in tumour size to half its original size. And after a year, no more new growths were detected. The findings have been published in the journal PLOS ONE.

Female rhinos often suffer from vaginal or uterus tumours which complicate the process of reproduction. Whilst they are largely innocuous, if they grow too much the animal may have reduced fertility, or become completely infertile. Tumours can cause pain during mating and lead to problems with conception, as well as miscarriages and stillborns. However, it is not possible to cut out large tumours owing to the rhino’s thick skin.

Improvac is a hormone that relates to the body’s gonadotrophin-releasing hormone (GnRH), which regulates the release of sexual hormones from the hypophysis and, therefore, ovulation and ovarian activity.

After vaccination, antibodies are produced that block GnRH so the hypophysis stops releasing sexual hormones and the oestrus cycle and female fertility cease. As a result, scientists say hormone-dependent tumours stop growing and reduce in size.

Tumour risk is linked to whether or not rhinos have previously had offspring. Gestation at an early age prevents reproductive organs from forming tumours and existing tumours stop growing when an animal gets pregnant. As a result, researchers from the Leibniz Institute for Zoo and Wildlife Research believe early reproduction of rhinos should be promoted.

Robert Hermes, an expert in reproductive medicine and rhinos from the institute, said: “If they are not able to have offspring because of external circumstances, for instance in the absence of an available mate, a vaccination could help prevent tumour formation.

“The sexual cycle is put ‘on ice’ and can be reactivated for pregnancy later on without loss of the female’s fertility or the risk of tumours.”

Further study will be needed to determine whether the vaccine’s effects are completely reversible. The same treatment has already been successfully used in horse mares, who became fertile again with a normal sexual cycle some time after vaccination.

Hermes continued: “If the oestrous cycle of female rhinoceros can be interrupted by a simple inoculation and, later on, fertility can recover again, the vaccination is a huge veterinary advance. This is a great benefit, particularly with regard to the future health care management of rhinos in human care.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.